Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Revolution Medicines, Inc.RVMD · Entity 606 | See Remarks | March 17, 2026 | March 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Revolution Medicines, Inc.
Report date March 17, 2026 · Filed March 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 116,063 |
Reported balance
After 2026-03-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-17 · Sale · Disposed 2,010 · Balance 116,063 F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on November 17, 2025 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after December 15, 2025. F2: Includes 48,700 RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on November 17, 2025 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after December 15, 2025.
F2: Includes 48,700 RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 17, 2026 Filed Mar 19, 2026 18:53 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 2,010 | $99.48 | $199,955.60 |
DisclosureSEC source: 0001610717-26-000126 · form4.xml · nonDerivative · entry 1 Wang Xiaolin · CIK 0001849181 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,063 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on November 17, 2025 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after December 15, 2025. F2 · balance_after: Includes 48,700 RSUs. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:11 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 34,000 | $0.00 Strike: $102.02 | $0.00 |
DisclosureSEC source: 0001610717-26-000085 · form4.xml · derivative · entry 2 Wang Xiaolin · CIK 0001849181 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2036-02-28 F3 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:11 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 15,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000085 · form4.xml · nonDerivative · entry 1 Wang Xiaolin · CIK 0001849181 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,073 F1 · balance_after: Includes 54,464 restricted stock units. F2 · balance_after: Includes 652 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2025. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 17:40 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GiftCommon Stock | 2,718 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000076 · form4.xml · nonDerivative · entry 1 Wang Xiaolin · CIK 0001849181 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,321 F1 · balance_after: Includes 56,650 restricted stock units. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 19:01 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 66,500 | $0.00 Strike: $40.74 | $0.00 |
DisclosureSEC source: 0001610717-25-000051 · form4.xml · derivative · entry 2 Wang Xiaolin · CIK 0001849181 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,500 Underlying: Common Stock · 66,500 shares Expires 2035-02-28 F3 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2025 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 19:01 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000051 · form4.xml · nonDerivative · entry 1 Wang Xiaolin · CIK 0001849181 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,039 F1 · balance_after: Includes 61,926 restricted stock units. F2 · balance_after: Includes 1,513 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2024. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 16:52 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 84,700 | $0.00 Strike: $29.80 | $0.00 |
DisclosureSEC source: 0001610717-24-000129 · form4.xml · derivative · entry 2 Wang Xiaolin · CIK 0001849181 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,700 Underlying: Common Stock · 84,700 shares Expires 2034-02-28 F3 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2024 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 16:52 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 24,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000129 · form4.xml · nonDerivative · entry 1 Wang Xiaolin · CIK 0001849181 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,526 F1 · balance_after: Includes 62,513 restricted stock units. F2 · balance_after: Includes 1,513 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2023. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 20:32 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 714 | $21.78 | $15,550.92 |
DisclosureSEC source: 0000899243-23-009372 · doc4.xml · nonDerivative · entry 1 Wang Xiaolin · CIK 0001849181 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,813 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the restricted stock units ("RSUs") award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: This transaction was executed in multiple trades in prices ranging from $21.4075 to $21.784581, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 49,600 RSUs. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 16:17 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 101,500 | $0.00 Strike: $26.50 | $0.00 |
DisclosureSEC source: 0001567619-23-004354 · doc1.xml · derivative · entry 2 Wang Xiaolin · CIK 0001849181 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,500 Underlying: Common Stock · 101,500 shares Expires 2033-02-28 F2 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2023 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 16:17 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 29,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-004354 · doc1.xml · nonDerivative · entry 1 Wang Xiaolin · CIK 0001849181 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,527 F1 · balance_after: Includes 51,550 restricted stock units. Read SEC document |
| December 19, 2022 Filed Dec 21, 2022 16:07 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 708 | $22.94 | $16,241.38 |
DisclosureSEC source: 0001567619-22-021928 · doc1.xml · nonDerivative · entry 1 Wang Xiaolin · CIK 0001849181 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,527 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the restricted stock units ("RSUs") award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: This transaction was executed in multiple trades in prices ranging from $22.4706 to $22.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 22,550 RSUs. Read SEC document |
| September 19, 2022 Filed Sep 21, 2022 16:18 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 735 | $19.04 | $13,996.31 |
DisclosureSEC source: 0001567619-22-017692 · doc1.xml · nonDerivative · entry 1 Wang Xiaolin · CIK 0001849181 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,235 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the restricted stock units ("RSUs") award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: This transaction was executed in multiple trades in prices ranging from $18.98 to $19.0337, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 24,500 RSUs. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 17:03 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 665 | $17.75 | $11,803.42 |
DisclosureSEC source: 0001567619-22-013253 · doc1.xml · nonDerivative · entry 1 Wang Xiaolin · CIK 0001849181 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,970 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the restricted stock units ("RSUs") award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes. F2 · balance_after: Includes 937 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2022. F3 · balance_after: Includes 26,450 RSUs. Read SEC document |
| March 17, 2022 Filed Mar 21, 2022 20:02 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 240 | $18.61 | $4,467.41 |
DisclosureSEC source: 0001567619-22-007325 · doc1.xml · nonDerivative · entry 1 Wang Xiaolin · CIK 0001849181 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,698 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: This transaction was executed in multiple trades in prices ranging from $18.1558 to $18.62, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 28,400 RSUs. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 16:25 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $18.56 | $0.00 |
DisclosureSEC source: 0001567619-22-006233 · doc1.xml · derivative · entry 2 Wang Xiaolin · CIK 0001849181 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2032-02-29 F2 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2022 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 16:25 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-006233 · doc1.xml · nonDerivative · entry 1 Wang Xiaolin · CIK 0001849181 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,938 F1 · balance_after: Includes 29,100 Restricted Stock Units. Read SEC document |
| December 17, 2021 Filed Dec 21, 2021 16:33 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 257 | $24.41 | $6,273.37 |
DisclosureSEC source: 0001567619-21-022404 · doc1.xml · nonDerivative · entry 1 Wang Xiaolin · CIK 0001849181 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,938 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · balance_after: Includes 9,100 RSUs. Read SEC document |
| September 17, 2021 Filed Sep 21, 2021 19:47 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 250 | $30.02 | $7,505.00 |
DisclosureSEC source: 0001567619-21-017415 · doc1.xml · nonDerivative · entry 1 Wang Xiaolin · CIK 0001849181 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,195 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · balance_after: Includes 9,800 RSUs. Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 17:19 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 243 | $34.12 | $8,291.38 |
DisclosureSEC source: 0001567619-21-012491 · doc1.xml · nonDerivative · entry 1 Wang Xiaolin · CIK 0001849181 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,445 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: This transaction was executed in multiple trades in prices ranging from $33.37 to $34.22, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 744 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2021. F4 · balance_after: Includes 10,500 RSUs. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 19:41 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 39,200 | $0.00 Strike: $42.45 | $0.00 |
DisclosureSEC source: 0001567619-21-005846 · doc1.xml · derivative · entry 2 Wang Xiaolin · CIK 0001849181 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,200 Underlying: Common Stock · 39,200 shares Expires 2031-03-03 F2 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 4, 2021 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 19:41 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 11,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-005846 · doc1.xml · nonDerivative · entry 1 Wang Xiaolin · CIK 0001849181 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,944 F1 · balance_after: Includes 11,200 Restricted Stock Units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.